临床试验/NCT00005577

NCT00005577已完成1 期

A PEDIATRIC PHASE I STUDY OF GEMCITABINE (NSC# 613327) IN SOLID TUMORS

National Cancer Institute (NCI)23 个研究点分布在 2 个国家目标入组 30 人开始时间: 1996年8月最近更新: 2013年2月5日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方: National Cancer Institute (NCI)
入组人数: 30
试验地点: 23

研究概览研究设计入排标准研究组 & 干预措施研究者研究点记录与标识符相似试验

研究概览

简要总结

Phase I trial to study the effectiveness of gemcitabine in treating children who have refractory solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

详细描述

OBJECTIVES:

I. Estimate the maximum tolerated dose of gemcitabine in children and adolescents with refractory solid tumors.

II. Assess the toxicity of gemcitabine in this patient population. III. Determine the pharmacokinetic profile of gemcitabine in male and female children and adolescents.

IV. Assess the antitumor activity of gemcitabine within a phase I study.

OUTLINE: This is a dose escalation study.

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 1 Year 至 21 Years（Child, Adult）
性别: All
接受健康志愿者: 否

入选标准

未提供

排除标准

未提供

研究组 & 干预措施

Arm I

Experimental

Patients receive gemcitabine IV over 30 minutes weekly for 2 weeks. Patients achieving objective response or stable disease after 3 weeks may receive additional courses of therapy every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of gemcitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicity.

干预措施: gemcitabine hydrochloride (Drug)

研究者

发起方

National Cancer Institute (NCI)

申办方类型

Nih

责任方

Sponsor

研究点 (23)

Loading locations...

相似试验

已完成

1 期

Gefitinib in Treating Children With Refractory Solid TumorsUnspecified Childhood Solid Tumor, Protocol Specific

NCT00040781National Cancer Institute (NCI)45

已完成

2 期

Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's LymphomaBrain and Central Nervous System TumorsUnspecified Childhood Solid Tumor, Protocol SpecificSarcomaLymphomaNeuroblastomaRetinoblastoma

NCT00006102National Cancer Institute (NCI)200

撤回

早期 1 期

Gemcitabine in Newly-Diagnosed Diffuse Midline GliomaGlial Tumor of BrainDiffuse Intrinsic Pontine GliomaGlioma

NCT04051047University of Michigan Rogel Cancer Center

进行中（未招募）

2 期

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialMalignant Solid NeoplasmRecurrent Adrenal Gland PheochromocytomaRecurrent EctomesenchymomaRecurrent EpendymomaRecurrent Ewing SarcomaRecurrent HepatoblastomaRecurrent Kidney Wilms TumorRecurrent Langerhans Cell HistiocytosisRecurrent Malignant Germ Cell TumorRecurrent Malignant GliomaRecurrent MedulloblastomaRecurrent MelanomaRecurrent NeuroblastomaRecurrent Non-Hodgkin LymphomaRecurrent OsteosarcomaRecurrent Peripheral Primitive Neuroectodermal TumorRecurrent Rhabdoid TumorRecurrent Rhabdoid Tumor of the KidneyRecurrent RhabdomyosarcomaRecurrent Soft Tissue SarcomaRecurrent Thyroid Gland CarcinomaRecurrent WHO Grade 2 GliomaRefractory Adrenal Gland PheochromocytomaRefractory EpendymomaRefractory Ewing SarcomaRefractory HepatoblastomaRefractory Langerhans Cell HistiocytosisRefractory Malignant Germ Cell TumorRefractory Malignant GliomaRefractory MedulloblastomaRefractory MelanomaRefractory NeuroblastomaRefractory Non-Hodgkin LymphomaRefractory OsteosarcomaRefractory Peripheral Primitive Neuroectodermal TumorRefractory Rhabdoid TumorRefractory Rhabdoid Tumor of the KidneyRefractory RhabdomyosarcomaRefractory Soft Tissue SarcomaRefractory Thyroid Gland CarcinomaRefractory WHO Grade 2 Glioma

NCT04284774National Cancer Institute (NCI)5

进行中（未招募）

2 期

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment TrialHematopoietic and Lymphatic System NeoplasmRecurrent EpendymomaRecurrent Ewing SarcomaRecurrent HepatoblastomaRecurrent Histiocytic and Dendritic Cell NeoplasmRecurrent Langerhans Cell HistiocytosisRecurrent LymphomaRecurrent Malignant Germ Cell TumorRecurrent Malignant GliomaRecurrent Malignant Solid NeoplasmRecurrent MedulloblastomaRecurrent NeuroblastomaRecurrent Non-Hodgkin LymphomaRecurrent OsteosarcomaRecurrent Peripheral Primitive Neuroectodermal TumorRecurrent Rhabdoid TumorRecurrent RhabdomyosarcomaRecurrent Soft Tissue SarcomaRecurrent WHO Grade 2 GliomaRefractory EpendymomaRefractory Ewing SarcomaRefractory HepatoblastomaRefractory Histiocytic and Dendritic Cell NeoplasmRefractory Langerhans Cell HistiocytosisRefractory LymphomaRefractory Malignant Germ Cell TumorRefractory Malignant GliomaRefractory Malignant Solid NeoplasmRefractory MedulloblastomaRefractory NeuroblastomaRefractory Non-Hodgkin LymphomaRefractory OsteosarcomaRefractory Peripheral Primitive Neuroectodermal TumorRefractory Rhabdoid TumorRefractory RhabdomyosarcomaRefractory Soft Tissue SarcomaRefractory WHO Grade 2 GliomaWilms Tumor

NCT04320888National Cancer Institute (NCI)1